NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that emerged from the de-SPAC merger between NeuroRx, Inc. and Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2018. The combined company, operating in the healthcare and specialty pharmaceuticals sector, filed an amended annual report on Form 10-K/A with the SEC on May 14, 2021, following the close of the business combination. NRX Pharmaceuticals has focused its pipeline on treatments for severe neurological and pulmonary conditions, including assets targeting bipolar depression and critical COVID-19 complications. Visit SpacDesk and sign up for full data, filings, and deal analytics on NRXP and hundreds of other SPAC transactions.